Unsurprising Tangent: MDMA For PTSD, “Hits The Wall” — Voted Down 10-1, At FDA Advisory Committee — “Risks Exceed Any Benefit”…

Not terribly surprising, as this had a bit of the game plan the Sacklers employed (on oxy-) — written all over it.

The relevant Advisory Committee at FDA yesterday voted 10-1 against approval, for a psychedelic candidate / controlled substance — as a putative treatment for post traumatic stress disorder.

From Seeking Alpha, then — a sensible squib:

…Psychedelic stocks Mind Medicine (NASDAQ:MNMD) dropped 10%, Atai Life Sciences (ATAI) -19%, COMPASS Pathways (CMPS) -15%, and Cybin (CYBN) -10% after the U.S. Food and Drug Administration voted against a therapy based on the mind-altering drug MDMA for patients with post-traumatic stress disorder, marking a setback to the nascent field of psychedelic treatments. The panel voted 10-to-1, stating that the benefits did not outweigh the risks and that the available data did not show its effectiveness….

Now you know, And I’m so sorry, Dr. Timothy Leary, but that time, it seems — is at an end. Smile.

नमस्ते